Seed Health closes $40m Series A funding round
Seed Health, a microbial sciences company developing next-generation probiotic applications and live biotherapeutics, today announced the close of a $40m Series A financing led by impact investor, The Craftory, alongside TechBio investor ARTIS Ventures and life science investor GISEV, with participation from existing investors, Founders Fund and 8VC.
This funding will support the company’s rapid growth and power upcoming category launches, clinical research, digital health initiatives, microbial stabilization technologies, and international expansion.
“Advances in research reveal the vast potential of microbes to transform how we live and care for ourselves, our children, and our environment. We are inspired to steward this next generation of probiotics and microbiome-based innovations that will disrupt and forever change the global categories of health, hygiene, diet and self-care,” said Ara Katz, Seed Health co-founder and co-CEO.
With the Company’s Scientific Board of leading microbiome researchers, clinicians and academic partners, Seed Health has assembled an Intellectual Property estate and Master Cell Bank (MCB) with microbial applications across gastroenterology, dermatology, oral hygiene, pediatrics, women’s health, and nutrition.
“We are converging advances in sequencing technologies, metabolomics, and functional strain characterization to gain insight into microbial communities and develop interventions that are effective across a heterogeneous population or personalized,” said Raja Dhir, Seed Health co-founder and co-CEO.
“These proceeds accelerate our multi-platform, multi-technology approach to efficiently take breakthrough research from discovery to market across ecosystems of the body at various life stages, developmental windows, and health conditions.”